157 related articles for article (PubMed ID: 12186421)
1. Effect of probucol on cytochrome P450 activities in human liver microsomes.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 Aug; 25(8):1112-4. PubMed ID: 12186421
[TBL] [Abstract][Full Text] [Related]
2. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2004 Jul; 27(7):1151-3. PubMed ID: 15256760
[TBL] [Abstract][Full Text] [Related]
3. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Jan; 27(1):97-9. PubMed ID: 14709907
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517
[TBL] [Abstract][Full Text] [Related]
5. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Mar; 27(3):415-7. PubMed ID: 14993813
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of carteolol by cDNA-expressed human cytochrome P450.
Kudo S; Uchida M; Odomi M
Eur J Clin Pharmacol; 1997; 52(6):479-85. PubMed ID: 9342584
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
9. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
10. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
11. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
12. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug.
Niwa T; Inoue S; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Jan; 28(1):188-91. PubMed ID: 15635191
[TBL] [Abstract][Full Text] [Related]
13. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
15. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
16. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
17. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys.
Nakanishi Y; Matsushita A; Matsuno K; Iwasaki K; Utoh M; Nakamura C; Uno Y
Drug Metab Pharmacokinet; 2011 Jun; 26(3):288-94. PubMed ID: 21273732
[TBL] [Abstract][Full Text] [Related]
18. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
19. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
20. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]